Panbela Therapeutics, Inc.
PBLA · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $7 | $8 | $7 | $7 |
| Gross Profit | -$7 | -$8 | -$7 | -$7 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $7 | $6 | $6 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7 | $8 | $7 | $7 |
| Operating Income | -$14 | -$8 | -$7 | -$7 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $7 | $1 | -$1 | $1 |
| Pre-Tax Income | -$7 | -$7 | -$7 | -$6 |
| Tax Expense | $0 | $0 | -$0 | -$0 |
| Net Income | -$7 | -$7 | -$7 | -$6 |
| % Margin | – | – | – | – |
| EPS | -1.48 | -1.47 | -2.28 | -0.027 |
| % Growth | -0.7% | 35.5% | -8,251.6% | – |
| EPS Diluted | -1.48 | -1.47 | -2.28 | -0.027 |
| Weighted Avg Shares Out | 5 | 5 | 3 | 237 |
| Weighted Avg Shares Out Dil | 5 | 5 | 3 | 237 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $0 | $0 |
| EBITDA | -$7 | -$6 | -$7 | -$6 |
| % Margin | – | – | – | – |